1. Short Course of Antifungal Therapy in Patients With Uncomplicated Candida Bloodstream Infection: Another Case of Less Is More in the Clinical Setting?
- Author
-
Vena, Antonio, Bovis, Francesca, Tutino, Stefania, Barbone, Alessandro Santagostino, Mezzogori, Laura, Ponzano, Marta, Taramasso, Lucia, Baldi, Federico, Dettori, Silvia, Labate, Laura, Russo, Chiara, Giacobbe, Daniele Roberto, Mikulska, Malgorzata, Dentone, Chiara, Magnasco, Laura, Marchese, Anna, Robba, Chiara, Ball, Lorenzo, Battaglini, Denise, and Pelosi, Paolo
- Subjects
CANDIDIASIS ,SEPTIC shock ,CANDIDEMIA ,DISEASE relapse ,MORTALITY ,CANDIDA - Abstract
Background The objective of this study was to compare the clinical outcomes of patients receiving a short course (SC) vs a prolonged course (PC) of antifungal therapy for uncomplicated Candida bloodstream infections (BSIs). Methods All episodes of uncomplicated Candida BSI from September 1, 2018, to August 31, 2020, were reviewed. We compared the primary (all-cause 90-day mortality) and secondary study end points (1-year recurrent Candida BSI and all-cause 1-year mortality) among patients who underwent SC (5–11 days) or PC (12–24 days) therapy using propensity score analysis with the inverse probability of treatment weighting (IPTW) method. Results A total of 114 patients with uncomplicated Candida BSI were included: 35 (30.7%) were classified into the SC group (median [interquartile range {IQR}], 9 [7–11] days) and 79 (69.3%) into the PC group (median [IQR], 14 [14–16] days). Patients in the SC group compared with the PC group had a higher rate of hospitalization in the surgical ward (40.0% vs 19.0%; P =.02) or septic shock at the time of Candida BSI onset (11.4% vs 1.3%; P =.03). The risk of 90-day mortality was not different between the SC and PC groups (n = 8 [22.9%] vs 17 [21.5%], respectively; IPTW-adjusted subdistribution hazard ratio [sHR], 0.67; 95% CI, 0.31–1.47; P =.20). The risk for recurrent Candida BSI within 1 year of completing therapy (IPTW-adjusted sHR, 1.07; 95% CI, 0.20–5.80; P =.94) or for all-cause 1-year mortality (IPTW-adjusted HR, 0.72; 95% CI, 0.35–1.50; P =.38) did not differ between groups. Conclusions Receiving a short vs prolonged course of antifungal therapy did not affect mortality or BSI recurrence in patients with uncomplicated candidemia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF